Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3681]

ESMO 35: New Phase II study shows first-line promise of lung cancer drug PF-299

ESMO 35: New Phase II study shows first-line promise of lung cancer drug PF-299

ESMO Session: Targeted agents in prostate cancer – Changing the paradigms – Improved inhibition of the androgen receptor

ESMO Session: Targeted agents in prostate cancer – Changing the paradigms – Improved inhibition of the androgen...

ESMO Presidential symposium: LBA5 – Abiraterone improves survival in mCRPC

ESMO Presidential symposium: LBA5 – Abiraterone improves survival in mCRPC

$ESMO 35: Pazopanib shows promise in Phase-II trial for relapse/refractory urothelial cancer$

ESMO 35: Pazopanib shows promise in Phase-II trial for relapse/refractory urothelial cancer

ESMO: Pazopanib in advanced MRCC – late breaker

ESMO: Pazopanib in advanced MRCC – late breaker

ESMO 35: Phase III study shows everolimus delays tumour progression in hard-to-treat neuroendocrine tumours

ESMO 35: Phase III study shows everolimus delays tumour progression in hard-to-treat neuroendocrine tumours

Insurance and socioeconomic status do not explain racial disparities in US breast cancer care

Insurance and socioeconomic status do not explain racial disparities in US breast cancer care

ESMO 35: Prolonging first-line chemotherapy improves outcomes for patients with metastatic breast cancer

ESMO 35: Prolonging first-line chemotherapy improves outcomes for patients with metastatic breast cancer

ESMO 35: Study finds breast-feeding safe for women after breast cancer treatment

ESMO 35: Study finds breast-feeding safe for women after breast cancer treatment

ESMO 35: Most Italian breast cancer patients older, and diagnosed very early

ESMO 35: Most Italian breast cancer patients older, and diagnosed very early

More from ecancer